Cel-Sci Corporation ($0.001 Par Value)
CVM
AMX
Sector: Healthcare
Industry: Biotechnology
4.00
USD
0.27
(7.24%)
Optionable: Yes Market Cap: 166 M 90-day average vol: 656,948
Previous close: 3.73 Open: 3.85 Bid: 4.0 Ask: 4.0
52 week range
2.49 12.90
Last updated: Friday 5th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 3.47 |
PE Ratio (TTM) | -4.10 |
Book Value per Share ($) | 1.04 |
5 Year PE Range-14.7 |
Returns
7 Day Return | 6.38% | |
1 Month Return | -4.08% | |
3 Month Return | 31.15% | |
1 Year Return | -54.70% | |
3 Year Return | -44.90% | |
5 Year Return | 73.91% | |
YTD Return | -43.66% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 51.23 |
14 Day SMA ($) | 3.80 |
14 Day EMA ($) | 3.88 |
Money Flow Index | 70.90 |
Average True Range | 0.34 |
50 Day SMA ($) | 3.94 |
200 Day SMA ($) | 5.88 |
ADX | 36.28 |
MACD | -0.07 |
Growth
Free Cash Flow QoQ Growth | -7.03% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 5.26% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
CVM: First Quarter Fiscal Year 2022 Results
Yahoo Finance 2/16/2022
Cel-Sci GAAP EPS of -$0.20
Seeking Alpha 2/14/2022
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
Yahoo Finance 2/14/2022
It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits.
Yahoo Finance 1/24/2022
CVM: FY21 Results; IO Revenues Analysis
Yahoo Finance 1/11/2022
Cel-Sci EPS misses by $0.70
Seeking Alpha 12/22/2021
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
Yahoo Finance 12/22/2021
CEL-SCI completes expansion of Multikine manufacturing facility
Seeking Alpha 10/22/2021
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
Yahoo Finance 10/22/2021
CVM: Primum Non Nocere
Yahoo Finance 8/25/2021
CEL-SCI's Tough Road Ahead
Seeking Alpha 8/20/2021
Cel-Sci reports Q3 results
Seeking Alpha 8/16/2021
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
Yahoo Finance 8/16/2021
CEL-SCI, Poised For Success, Is A Seriously Big Opportunity (Part II)
Seeking Alpha 8/11/2021
CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors
Seeking Alpha 7/14/2021
CVM: Data Has Been Released
Yahoo Finance 7/8/2021
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CEL-SCI Corporation - CVM
Yahoo Finance 7/8/2021
Why CEL-SCI Stock Soared Today
Yahoo Finance 7/7/2021
CEL-SCI says analysis of successful study arm was pre-specified in protocol
Seeking Alpha 7/7/2021
CEL-SCI Corporation Issues Letter to Shareholders
Yahoo Finance 7/7/2021
Cel-Sci's Pivotal Phase 3 Results Are In: The Drama Continues
Seeking Alpha 7/6/2021
3 Biotechs to Avoid Like the Plague in July
Yahoo Finance 7/6/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Financials
CVM Income Statement
Annual
| Sep-12 | Sep-13 | Sep-14 | Sep-15 | Sep-16 | Sep-17 | Sep-18 | Sep-19 | Sep-20 | Sep-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of sales | -533468 | -364124 | -745496 | -720494 | -663988 | -632915 | -650131 | -633529 | -2 M | -2 M |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling Gen & administrative expense | 6 M | 7 M | 10 M | 13 M | 6 M | 6 M | 6 M | 8 M | 11 M | 13 M |
| Research & development expense | 10 M | 13 M | 15 M | 19 M | 17 M | 16 M | 11 M | 13 M | 18 M | 23 M |
| Operating income | -17 M | -20 M | -26 M | -32 M | -24 M | -21 M | -17 M | -20 M | -29 M | -36 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 2 M | 11 M | 248767 | -337841 | 14 M | 11 M | -11 M | -142053 | -228464 | 982308 |
| Pre-tax Income (EBT) | -15 M | -9 M | -27 M | -35 M | -12 M | -14 M | -32 M | -22 M | -30 M | -36 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -15 M | -9 M | -27 M | -35 M | -12 M | -14 M | -32 M | -22 M | -30 M | -36 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -15 M | -9 M | -27 M | -35 M | -12 M | -14 M | -32 M | -22 M | -30 M | -36 M |
| Preferred dividends | 250000 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -15 M | -9 M | -27 M | -35 M | -12 M | -14 M | -32 M | -22 M | -30 M | -36 M |
| Depreciation | 533468 | 364124 | 745496 | 720494 | 663988 | 632915 | 650131 | 633529 | 2 M | 2 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -15 M | -9 M | -25 M | -32 M | -23 M | -21 M | -16 M | -20 M | -27 M | -33 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -17.5 | -7.5 | -12 | -10.5 | -2.25 | -1.83 | -1.87 | -0.71 | -0.82 | -0.9 |
| Diluted EPS total | -17.5 | -16.5 | -12.25 | -10.5 | -2.25 | -1.91 | -1.87 | -0.71 | -0.82 | -0.93 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!